PURPOSE: We conducted extensive epidemiological, neuro-ophthalmological, psychophysical, and blood examinations on a newly discovered, very large pedigree with molecular analysis showing mtDNA mutation for Leber's hereditary optic neuropathy (LHON). METHODS: Four patients representing four index cases from a remote area of Brazil were sent to Sao Paulo, where complete ophthalmological examinations strongly suggested LHON. Molecular analysis of their blood demonstrated that they were LHON, homoplasmic 11778, J-haplogroup. They had an extensive family that all lived in one rural area in Brazil. To investigate this family, we drew on a number of international experts to form a team that traveled to Brazil. This field team also included several members of the Federal University of Sao Paulo, and together we evaluated 273 of the 295 family members that were still alive. We conducted epidemiological interviews emphasizing possible environmental risk factors, comprehensive neuro-ophthalmological examinations, psychophysical tests, Humphrey visual field studies, fundus photography, and blood testing for both mitochondrial genetic analysis and nuclear gene linkage analysis. RESULTS: The person representing the first-generation case immigrated from Verona, Italy, to Colatina. Subsequent generations demonstrated penetrance rates of 71%, 60%, 34%, 15%, and 9%. The percentages of males were 60%, 50%, 64%, 100%, and 100%. Age at onset varied from 10 to 64 years, and current visual acuities varied from LP to 20/400. CONCLUSIONS: Almost 95% of a nearly 300-member pedigree with LHON 11778 were comprehensively studied. Analysis of environmental risk factors and a nuclear modifying factor from this group may help address the perplexing mystery of LHON: Why do only some of the genetically affected individuals manifest the disease? This fully described database may also provide an excellent opportunity for future clinical trials of any purported neuroprotective agent.
PURPOSE: We conducted extensive epidemiological, neuro-ophthalmological, psychophysical, and blood examinations on a newly discovered, very large pedigree with molecular analysis showing mtDNA mutation for Leber's hereditary optic neuropathy (LHON). METHODS: Four patients representing four index cases from a remote area of Brazil were sent to Sao Paulo, where complete ophthalmological examinations strongly suggested LHON. Molecular analysis of their blood demonstrated that they were LHON, homoplasmic 11778, J-haplogroup. They had an extensive family that all lived in one rural area in Brazil. To investigate this family, we drew on a number of international experts to form a team that traveled to Brazil. This field team also included several members of the Federal University of Sao Paulo, and together we evaluated 273 of the 295 family members that were still alive. We conducted epidemiological interviews emphasizing possible environmental risk factors, comprehensive neuro-ophthalmological examinations, psychophysical tests, Humphrey visual field studies, fundus photography, and blood testing for both mitochondrial genetic analysis and nuclear gene linkage analysis. RESULTS: The person representing the first-generation case immigrated from Verona, Italy, to Colatina. Subsequent generations demonstrated penetrance rates of 71%, 60%, 34%, 15%, and 9%. The percentages of males were 60%, 50%, 64%, 100%, and 100%. Age at onset varied from 10 to 64 years, and current visual acuities varied from LP to 20/400. CONCLUSIONS: Almost 95% of a nearly 300-member pedigree with LHON 11778 were comprehensively studied. Analysis of environmental risk factors and a nuclear modifying factor from this group may help address the perplexing mystery of LHON: Why do only some of the genetically affected individuals manifest the disease? This fully described database may also provide an excellent opportunity for future clinical trials of any purported neuroprotective agent.
Authors: D C Wallace; G Singh; M T Lott; J A Hodge; T G Schurr; A M Lezza; L J Elsas; E K Nikoskelainen Journal: Science Date: 1988-12-09 Impact factor: 47.728
Authors: P Klivenyi; E Karg; C Rozsa; R Horvath; S Komoly; I Nemeth; S Turi; L Vecsei Journal: J Neurol Neurosurg Psychiatry Date: 2001-03 Impact factor: 10.154
Authors: J B Kerrison; N R Miller; F Hsu; T H Beaty; I H Maumenee; K H Smith; P J Savino; E M Stone; N J Newman Journal: Am J Ophthalmol Date: 2000-12 Impact factor: 5.258
Authors: Steven R Danielson; Alice Wong; Valerio Carelli; Andrea Martinuzzi; Anthony H V Schapira; Gino A Cortopassi Journal: J Biol Chem Date: 2001-12-11 Impact factor: 5.157
Authors: Billy X Pan; Fred N Ross-Cisneros; Valerio Carelli; Kelly S Rue; Solange R Salomao; Milton N Moraes-Filho; Milton N Moraes; Adriana Berezovsky; Rubens Belfort; Alfredo A Sadun Journal: Invest Ophthalmol Vis Sci Date: 2012-11-09 Impact factor: 4.799
Authors: Kenneth M Yee; Fred N Ross-Cisneros; Jeong Goo Lee; Arlon Bastos Da Rosa; Solange R Salomao; Adriana Berezovsky; Rubens Belfort; Filipe Chicani; Milton Moraes-Filho; Jerry Sebag; Valerio Carelli; Alfredo A Sadun Journal: Invest Ophthalmol Vis Sci Date: 2012-09-21 Impact factor: 4.799
Authors: P A Quiros; R J Torres; S Salomao; A Berezovsky; V Carelli; J Sherman; F Sadun; A De Negri; R Belfort; A A Sadun Journal: Br J Ophthalmol Date: 2006-02 Impact factor: 4.638
Authors: Ana Laura A Moura; Balázs V Nagy; Chiara La Morgia; Piero Barboni; André Gustavo Fernandes Oliveira; Solange R Salomão; Adriana Berezovsky; Milton Nunes de Moraes-Filho; Carlos Filipe Chicani; Rubens Belfort; Valerio Carelli; Alfredo A Sadun; Donald C Hood; Dora Fix Ventura Journal: Invest Ophthalmol Vis Sci Date: 2013-07-02 Impact factor: 4.799
Authors: John Guy; Gerry Shaw; Fred N Ross-Cisneros; Peter Quiros; Solange R Salomao; Adriana Berezovsky; Valerio Carelli; William J Feuer; Alfredo A Sadun Journal: Mol Vis Date: 2008-12-22 Impact factor: 2.367